WE CLAIM:

1. A bicyclic imidazo-5-yl-amine of formula I



I

wherein

R^1 denotes $C(CH_3)_3$; $(CH_2)_6CN$; optionally substituted phenyl; C_4-C_8-cycloalkyl; CH_2CH_2R (R = 4-morpholino); 1,1,3,3-tetramethylbutyl; or CH_2R^a, wherein R^a represents hydrogen, branched or unbranched C_1-C_8-alkyl, optionally substituted phenyl, CO(OR') (where R' = branched or unbranched C_1-C_8-alkyl), $PO(OR'')_2$ (where R'' = branched or unbranched C_1-C_4-alkyl) or $Si(R^xR^yR^z)$ (where R^x, R^y and R^z in each case independently of one another are branched or unbranched C_1-C_8-alkyl, C_4-C_8-cycloalkyl or phenyl),

R^2 denotes hydrogen; COR^b, wherein R^b represents hydrogen, branched or unbranched C_1-C_8-alkyl, C_3-C_8-cycloalkyl, $CH_2CH_2CO(OR')$ (where R' = branched or unbranched C_1-C_8-alkyl), adamantyl, optionally substituted phenyl, optionally substituted 1-naphthyl, 2-naphthyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, thiazolyl or furoyl; CH_2R^c, wherein R^c represents hydrogen, branched or unbranched C_1-C_8-alkyl or optionally substituted phenyl; $CH_2CH_2R^d$, wherein R^d represents optionally substituted phenyl; or $CONHR^e$, wherein R^e represents phenyl,

R^3 denotes branched or unbranched C_1-C_8-alkyl, C_3-C_8-cycloalkyl, optionally substituted phenyl, optionally substituted 1-naphthyl, 2-naphthyl, quinoline, anthracene, phenanthrene, benzothiophene, benzofurfuryl, optionally

substituted pyrrole, 2-pyridyl, 3-pyridyl, 4-pyridyl, optionally substituted furfuryl or optionally substituted thiophene,

X denotes CR^5, N or S, and

Y is N, or if X is S, then Y may also be CR^6,

R^4, R^5 and R^6 independently of one another denote hydrogen; branched or unbranched C_1-C_8-alkyl; fluorine; chlorine; bromine; CF_3; CN; NO_2; NHR^f, wherein R^f represents hydrogen, branched or unbranched C_1-C_8-alkyl or optionally substituted phenyl; SR^g, wherein R^g represents hydrogen, branched or unbranched C_1-C_8-alkyl, phenyl, pyridine, benzyl or fluorenyl; OR^h, wherein R^h represents branched or unbranched C_1-C_8-alkyl, optionally substituted phenyl or CO(OR') (R' = branched or unbranched C_1-C_8-alkyl); CO(OR') or $CH_2CO(OR')$, wherein R' in each case has the abovementioned meaning or in the case of the group $CH_2CO(OR')$ also denotes hydrogen, or an optionally substituted phenyl group,

wherein optionally substituted phenyl, optionally substituted 1-naphthyl, optionally substituted pyrrole, optionally substituted furfuryl, optionally substituted thiophene, and optionally substituted alkyl is optionally substituted by one or more substituents selected from the group consisting of a halogen atom, cyano group, nitro group, carboxyl group, hydroxyl group, C_1-C_4 alkylamido group, C_1-C_4 alkylamino group, pyrrolidino group, branched or unbranched C_1-C_6 alkyl group, C_1-C_4 alkyl group substituted with one or more halogen atoms, C_1-C_4 alkoxy group, C_1-C_4 alkoxy group substituted with one or more halogen atoms, and halogen substituted phenoxy group,

or a pharmaceutically acceptable salt thereof,

excluding compounds in which simultaneously R^1 denotes $C(CH_3)_3$, R^2 denotes hydrogen, R^3 denotes unsubstituted phenyl, X denotes S, and Y denotes N or CR^6, where R^6 = hydrogen or CH_2-CO_2-ethyl, or simultaneously R^1 denotes

$C(CH_3)_3$, R^2 denotes hydrogen, R^3 denotes unsubstituted phenyl, Y denotes NH, and X denotes N or CR^5, where $R^5 = CO_2$ethyl.

2. A bicyclic imidazo-5-yl-amine according to claim 1,

wherein R^3 is a substituted phenyl group selected from the group consisting of 4-acetamidophenyl, 2-bromophenyl, 3-bromophenyl, 4-bromophenyl, 4-bromo-2-fluorophenyl, 5-bromo-2-fluorophenyl, 3-bromo-4-fluorophenyl, 4-*tert*-butylphenyl, 2-chloro-4-fluorophenyl, 2-chloro-6-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 4-cyanophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 2,3-dimethoxyphenyl, 3,4-dimethoxyphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 4-hexylphenyl, 3-hydroxyphenyl, 2-methoxyphenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 4-nitrophenyl, 3-phenoxyphenyl, 4-(1-pyrrolidino)phenyl, 2-(trifluoromethyl)phenyl, 3-(trifluoromethyl)phenyl, 4-(trifluoromethyl)phenyl, 3,4,5-trimethoxyphenyl, 3-(4-chlorophenoxy)phenyl and 4-acetoxy-3-methoxyphenyl,

or R^3 is a substituted 1-naphthyl group selected from the group consisting of 4-dimethylaminonaphthyl, 2-ethoxynaphthyl and 4-methoxynaphthyl,

or R^3 is a substituted pyrrole group selected from the group consisting of 2-(1-(phenylsulfonyl)pyrrole), 2-(N-methylpyrrole), 2-(N-(3,5-dichlorophenyl)pyrrole and 2-(1-(4-chlorophenyl)pyrrole),

or R^3 is a substituted furfuryl group selected from the group consisting of 2-(5-acetoxymethylfurfuryl), 2-(5-methylfurfuryl), 2-(5-nitrofurfuryl), 2-[5-(3-nitrophenyl)furfuryl], 2-[5-(2-nitrophenyl)furfuryl], 2-(5-bromofurfuryl), 2-[5-(4-chlorophenyl)furfuryl], 2-(4,5-dimethylfurfuryl), 2-[5-(2-chlorophenyl)furfuryl], 2-(5-ethylfurfuryl) and 2-[5-(1,3-dioxalane)furfuryl],

or R^3 is a substituted thiophene group, selected from the group consisting of 2-(5-chlorothiophenyl), 2-(5-methylthiophenyl), 2-(5-ethylthiophenyl), 2-(3-

methylthiophenyl), 2-(4-bromothiophenyl), 2-(5-nitrothiophenyl), 5-(2-carboxythiophenyl), 2-[4-(phenylethyl)thiophenyl], 2-[5-(methylthio)thiophenyl], 2-(3-bromothiophenyl), 2-(3-phenoxythiophenyl) and 2-(5-bromothiophenyl).

3. A bicyclic imidazo-5-yl-amine according to claim 1, wherein R^b is a substituted phenyl group selected from the group consisting of 3,5-bis(trifluoromethyl)phenyl, 2-bromophenyl, 2-fluorophenyl, pentafluorophenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 2-chlorophenyl, 2,4-dichlorophenyl, 2-acetylphenyl, 2-methoxyphenyl, 2,6-dimethoxyphenyl, 2-(trifluoromethyl)phenyl, 2-methylphenyl, 3-bromophenyl, 3-fluorophenyl, 3-chlorophenyl, 3,4-dichlorophenyl, 3-methoxyphenyl, 3,4-dimethoxyphenyl, 3,4,5-trimethoxyphenyl, 3,5-dimethoxyphenyl, 3-(trifluoromethyl)phenyl, 3-methoxyphenyl, 4-bromophenyl, 4-fluorophenyl, 4-chlorophenyl, 4-methoxyphenyl, 4-(trifluoromethyl)phenyl, 4-*tert*-butylphenyl, 4-methylphenyl, 2-iodophenyl, 4-iodophenyl, 4-cyanophenyl, 2-nitrophenyl, 3-nitrophenyl, 3,5-dinitrophenyl, 4-nitrophenyl, 3,5-dichlorophenyl, 2,5-difluorophenyl, 2,4-dimethoxyphenyl, 3-nitro-4-methylphenyl, 2,5-dichlorophenyl, 2,3-difluorophenyl, 4-(trifluoromethoxy)phenyl, 2-(trifluoromethoxy)phenyl, and 3-(trifluoromethoxy)phenyl.

4. A bicyclic imidazo-5-yl-amine according to claim 1, wherein R^c is a substituted phenyl group selected from the group consisting of 2-fluorophenyl, 2-chlorophenyl, 2-methylphenyl 2-(trifluoromethyl)phenyl, 2-bromophenyl, 3-methoxyphenyl, 3-nitrophenyl, 3-chlorophenyl, 3-fluorophenyl, 3-phenoxyphenyl, 3-(trifluoromethoxy)phenyl, 3-bromophenyl, 3-chlorophenyl, 3-methylphenyl, 4-*tert*-butylphenyl, 4-fluorophenyl, 4-chlorophenyl, 4-vinylphenyl, 4-(trifluoromethoxy)phenyl, 3,5-dimethoxyphenyl, 3,5-difluorophenyl, 3,5-di(trifluoromethyl)phenyl, 3,5-difluorophenyl, 3,5-dimethylphenyl 2,3-dichlorophenyl, 2,3-dimethylphenyl, 2,3-difluorophenyl, 3-chloro-2-fluorophenyl, 2-chloro-4-fluorophenyl, 2,4-di(trifluoromethyl)phenyl, 2,4-dichlorophenyl, 2,4-difluorophenyl, 2,4-dimethylphenyl, 2,5-dichlorophenyl, 2,5-dimethylphenyl, 2,5-

difluorophenyl, 3,4-dichlorophenyl, 3,4-difluorophenyl, 3,4-dimethylphenyl, 2,3,4-trifluorophenyl, 2,3,6-trifluorophenyl, 2,4,5-trifluorophenyl, 2,4,6-trimethylphenyl and pentafluorophenyl.

5. A bicyclic imidazo-5-yl-amine according to claim 1, wherein R^d is a substituted phenyl group selected from the group consisting of 3-chlorophenyl, 4-chlorophenyl, 4-carboxyphenyl, 4-acetylphenyl, 4-methoxyphenyl, 4-fluorophenyl, 4-nitrophenyl and 4-hydroxyphenyl.

6. A bicyclic imidazo-5-yl-amine selected from the group consisting of

tert-butyl-(5-furan-2-yl-imidazo[1,2-b][1,2,4]triazol-6-yl)-amine,

tert-butyl-(6-furan-2-yl-imidazo[2,1-b]thiazol-5-yl)-amine,

(5-*tert*-butylamino-6-furan-2-yl-imidazo[2,1-b]thiazol-3-yl)-acetic acid,

tert-butyl-(5-pyridin-2-yl-imidazo[1,2-b][1,2,4]triazol-6-yl)-amine,

tert-butyl-(6-pyridin-2-yl-imidazo[2,1-b]thiazol-5-yl)-amine,

tert-butyl-(5-pyridin-3-yl-imidazo[1,2-b][1,2,4]triazol-6-yl)-amine,

tert-butyl-(5-pyridin-4-yl-imidazo[1,2-b][1,2,4]triazol-6-yl)-amine,

tert-butyl-(6-cyclohexyl-imidazo[2,1-b]thiazol-5-yl)-amine,

tert-butyl-(5-methyl-imidazo[1,2-b][1,2,4]triazol-6-yl)-amine,

tert-butyl-(6-methyl-imidazo[2,1-b]thiazol-5-yl)-amine,

cyclohexyl-(5-pyridin-2-yl-imidazo[1,2-b][1,2,4]triazol-6-yl)-amine,

cyclohexyl-(6-pyridin-2-yl-imidazo[2,1-b]thiazol-5-yl)-amine,

(5-cyclohexylamino-6-pyridin-2-yl-imidazo[2,1-b]thiazol-3-yl)-acetic acid,

cyclohexyl-(6-pyridin-4-yl-imidazo[2,1-b]thiazol-5-yl)-amine,

cyclohexyl-(6-cyclohexyl-imidazo[2,1-b]thiazol-5-yl)-amine,

(6-cyclohexyl-5-cyclohexylamino-imidazo[2,1-b]thiazol-3-yl)-acetic acid,

(5-cyclohexylamino-6-methyl-imidazo[2,1-b]thiazol-3-yl)-acetic acid,

(2,6-dimethyl-phenyl)-(5-furan-2-yl-imidazo[1,2-b][1,2,4]triazol-6-yl)-amine,

(2,6-dimethyl-phenyl)-(6-pyridin-2-yl-imidazo[2,1-b]thiazol-5-yl)-amine,

(2,6-dimethyl-phenyl)-(6-pyridin-3-yl-imidazo[2,1-b]thiazol-5-yl)-amine,

(2,6-dimethyl-phenyl)-(6-pyridin-4-yl-imidazo[2,1-b]thiazol-5-yl)-amine,

methyl (6-cyclohexyl-imidazo[2,1-b]thiazol-5-ylamino)-acetate,

methyl (6-methyl-imidazo[2,1-b]thiazol-5-ylamino)-acetate,

tert-butyl-(2-phenyl-5H-imidazo[1,2-b]pyrazol-3-yl)-amine,

3-(5-*tert*-butylamino-imidazo[2,1-b]thiazol-6-yl)-phenol,

tert-butyl-[6-(3,4-dimethoxy-phenyl)-imidazo[2,1-b]thiazol-5-yl]-amine,

tert-butyl-[5-(2,3-dichloro-phenyl)-imidazo[1,2-b][1,2,4]triazol-6-yl]-amine,

tert-butyl-[6-(2,3-dichloro-phenyl)-imidazo[2,1-b]thiazol-5-yl]-amine,

tert-butyl-[5-(2,4-dichloro-phenyl)-imidazo[1,2-b][1,2,4]triazol-6-yl]-amine,

tert-butyl-[6-(2,4-dichloro-phenyl)-imidazo[2,1-b]thiazol-5-yl]-amine,

tert-butyl-[5-(2-methoxy-phenyl)-imidazo[1,2-b][1,2,4]triazol-6-yl]-amine,

tert-butyl-[6-(2-methoxy-phenyl)-imidazo[2,1-b]thiazol-5-yl]-amine,

[5-*tert*-butylamino-6-(2-methoxy-phenyl)-imidazo[2,1-b]thiazol-3-yl]-acetic acid,

tert-butyl-(5-o-tolyl-imidazo[1,2-b][1,2,4]triazol-6-yl)-amine,

tert-butyl-(6-o-tolyl-imidazo[2,1-b]thiazol-5-yl)-amine,

tert-butyl-[5-(2,3-dimethoxy-phenyl)-imidazo[1,2-b][1,2,4]triazol-6-yl]-amine,

tert-butyl-[6-(2,3-dimethoxy-phenyl)-imidazo[2,1-b]thiazol-5-yl]-amine,

tert-butyl-(6-p-tolyl-imidazo[2,1-b]thiazol-5-yl)-amine,

(5-*tert*-butylamino-6-methyl-imidazo[2,1-b]thiazol-3-yl)-acetic acid,

N-*tert*-butyl-N-(6-phenyl-imidazo[2,1-b]thiazol-5-yl)-acetamide,

N-*tert*-butyl-N-(6-o-tolyl-imidazo[2,1-b]thiazol-5-yl)-acetamide,

butyl-[6-(4-*tert*-butyl-phenyl)-2-methyl-imidazo[2,1-b]thiazol-5-yl]amine,

tert-butyl-[5-(2-fluorophenyl)-imidazo[1,2-b][1,2,4]triazol-6-yl]-amine,

tert-butyl-[6-(2-fluorophenyl)-imidazo[2,1-b]thiazol-5-yl]-amine,

tert-butyl-(5-naphthalen-1-yl-imidazo[1,2-b][1,2,4]triazol-6-yl)-amine,

cyclohexyl-(5-naphthalen-1-yl-imidazo[1,2-b][1,2,4]triazol-6-yl)-amine,

[5-(2-bromophenyl)-imidazo[1,2-b][1,2,4]triazol-6-yl]-(1,1,3,3-tetramethyl-butyl)-amine,

N-[4-(6-cyclohexylamino-imidazo[1,2-b][1,2,4]triazol-5-yl)-phenyl)-acetamide,

tert-butyl-[5-(2,5-dimethyl-phenyl)-imidazo[1,2-b][1,2,4]triazol-6-yl]-amine,

cyclohexyl-[6-(2,4-dimethyl-phenyl)-imidazo[2,1-b]thiazol-5-yl]-amine,

cyclohexyl-[6-(2,5-dimethylphenyl)-imidazo[2,1-b]thiazol-5-yl]-amine,

N-*tert*-butyl-N-(6-p-tolyl-imidazo[2,1-b]thiazol-5-yl)-acetamide,

[5-(2,4-dimethyl-phenyl)-imidazo[1,2-b][1,2,4]triazol-6-yl]-(1,1,3,3-tetramethyl-butyl)-amine,

[5-(2,5-dimethyl-phenyl)-imidazo[1,2-b][1,2,4]triazol-6-yl]-(1,1,3,3-tetramethyl-butyl)-amine,

N-butyl-N-[5-(2-chloro-6-fluorophenyl)-imidazo[1,2-b][1,2,4]triazol-6-yl]-acetamide and

N-butyl-N-[6-(4-*tert*-butyl-phenyl)-2-methyl-imidazo[2,1-b]thiazol-5-yl]-acetamide

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising at least one pharmaceutically active bicyclic imidazo-5-yl-amine according to Claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

8. A pharmaceutical composition according to Claim 7, wherein the at least one bicyclic imidazo-5-yl-amine is selected from the group consisting of

tert-butyl-(5-furan-2-yl-imidazo[1,2-b][1,2,4]triazol-6-yl)-amine,

tert-butyl-(6-furan-2-yl-imidazo[2,1-b]thiazol-5-yl)-amine,

(5-*tert*-butylamino-6-furan-2-yl-imidazo[2,1-b]thiazol-3-yl)-acetic acid,

tert-butyl-(5-pyridin-2-yl-imidazo[1,2-b][1,2,4]triazol-6-yl)-amine,

tert-butyl-(6-pyridin-2-yl-imidazo[2,1-b]thiazol-5-yl)-amine,

tert-butyl-(5-pyridin-3-yl-imidazo[1,2-b][1,2,4]triazol-6-yl)-amine,

tert-butyl-(5-pyridin-4-yl-imidazo[1,2-b][1,2,4]triazol-6-yl)-amine,

tert-butyl-(6-cyclohexyl-imidazo[2,1-b]thiazol-5-yl)-amine,

tert-butyl-(5-methyl-imidazo[1,2-b][1,2,4]triazol-6-yl)-amine,

tert-butyl-(6-methyl-imidazo[2,1-b]thiazol-5-yl)-amine,

cyclohexyl-(5-pyridin-2-yl-imidazo[1,2-b][1,2,4]triazol-6-yl)-amine,

cyclohexyl-(6-pyridin-2-yl-imidazo[2,1-b]thiazol-5-yl)-amine,

(5-cyclohexylamino-6-pyridin-2-yl-imidazo[2,1-b]thiazol-3-yl)-acetic acid,

cyclohexyl-(6-pyridin-4-yl-imidazo[2,1-b]thiazol-5-yl)-amine,

cyclohexyl-(6-cyclohexyl-imidazo[2,1-b]thiazol-5-yl)-amine,

(6-cyclohexyl-5-cyclohexylamino-imidazo[2,1-b]thiazol-3-yl)-acetic acid,

(5-cyclohexylamino-6-methyl-imidazo[2,1-b]thiazol-3-yl)-acetic acid,

(2,6-dimethyl-phenyl)-(5-furan-2-yl-imidazo[1,2-b][1,2,4]triazol-6-yl)-amine,

(2,6-dimethyl-phenyl)-(6-pyridin-2-yl-imidazo[2,1-b]thiazol-5-yl)-amine,

(2,6-dimethyl-phenyl)-(6-pyridin-3-yl-imidazo[2,1-b]thiazol-5-yl)-amine,

(2,6-dimethyl-phenyl)-(6-pyridin-4-yl-imidazo[2,1-b]thiazol-5-yl)-amine,

methyl (6-cyclohexyl-imidazo[2,1-b]thiazol-5-ylamino)-acetate,

methyl (6-methyl-imidazo[2,1-b]thiazol-5-ylamino)-acetate,

tert-butyl-(2-phenyl-5H-imidazo[1,2-b]pyrazol-3-yl)-amine,

3-(5-*tert*-butylamino-imidazo[2,1-b]thiazol-6-yl)-phenol,

tert-butyl-[6-(3,4-dimethoxy-phenyl)-imidazo[2,1-b]thiazol-5-yl]-amine,

tert-butyl-[5-(2,3-dichloro-phenyl)-imidazo[1,2-b][1,2,4]triazol-6-yl]-amine,

tert-butyl-[6-(2,3-dichloro-phenyl)-imidazo[2,1-b]thiazol-5-yl]-amine,

tert-butyl-[5-(2,4-dichloro-phenyl)-imidazo[1,2-b][1,2,4]triazol-6-yl]-amine,

tert-butyl-[6-(2,4-dichloro-phenyl)-imidazo[2,1-b]thiazol-5-yl]-amine,

tert-butyl-[5-(2-methoxy-phenyl)-imidazo[1,2-b][1,2,4]triazol-6-yl]-amine,

tert-butyl-[6-(2-methoxy-phenyl)-imidazo[2,1-b]thiazol-5-yl]-amine,

[5-*tert*-butylamino-6-(2-methoxy-phenyl)-imidazo[2,1-b]thiazol-3-yl]-acetic acid,

tert-butyl-(5-o-tolyl-imidazo[1,2-b][1,2,4]triazol-6-yl)-amine,

tert-butyl-(6-o-tolyl-imidazo[2,1-b]thiazol-5-yl)-amine,

tert-butyl-[5-(2,3-dimethoxy-phenyl)-imidazo[1,2-b][1,2,4]triazol-6-yl]-amine,

tert-butyl-[6-(2,3-dimethoxy-phenyl)-imidazo[2,1-b]thiazol-5-yl]-amine,

tert-butyl-(6-p-tolyl-imidazo[2,1-b]thiazol-5-yl)-amine,

(5-*tert*-butylamino-6-methyl-imidazo[2,1-b]thiazol-3-yl)-acetic acid,

N-*tert*-butyl-N-(6-phenyl-imidazo[2,1-b]thiazol-5-yl)-acetamide,

N-*tert*-butyl-N-(6-o-tolyl-imidazo[2,1-b]thiazol-5-yl)-acetamide,

butyl-[6-(4-*tert*-butyl-phenyl)-2-methyl-imidazo[2,1-b]thiazol-5-yl]amine,

tert-butyl-[5-(2-fluorophenyl)-imidazo[1,2-b][1,2,4]triazol-6-yl]-amine,

tert-butyl-[6-(2-fluorophenyl)-imidazo[2,1-b]thiazol-5-yl]-amine,

tert-butyl-(5-naphthalen-1-yl-imidazo[1,2-b][1,2,4]triazol-6-yl)-amine,

cyclohexyl-(5-naphthalen-1-yl-imidazo[1,2-b][1,2,4]triazol-6-yl)-amine,

[5-(2-bromophenyl)-imidazo[1,2-b][1,2,4]triazol-6-yl]-(1,1,3,3-tetramethyl-butyl)-amine,

N-[4-(6-cyclohexylamino-imidazo[1,2-b][1,2,4]triazol-5-yl)-phenyl)-acetamide,

tert-butyl-[5-(2,5-dimethyl-phenyl)-imidazo[1,2-b][1,2,4]triazol-6-yl]-amine,

cyclohexyl-[6-(2,4-dimethyl-phenyl)-imidazo[2,1-b]thiazol-5-yl]-amine,

cyclohexyl-[6-(2,5-dimethylphenyl)-imidazo[2,1-b]thiazol-5-yl]-amine,

N-*tert*-butyl-N-(6-p-tolyl-imidazo[2,1-b]thiazol-5-yl)-acetamide,

[5-(2,4-dimethyl-phenyl)-imidazo[1,2-b][1,2,4]triazol-6-yl]-(1,1,3,3-tetramethyl-butyl)-amine,

[5-(2,5-dimethyl-phenyl)-imidazo[1,2-b][1,2,4]triazol-6-yl]-(1,1,3,3-tetramethyl-butyl)-amine,

N-butyl-N-[5-(2-chloro-6-fluorophenyl)-imidazo[1,2-b][1,2,4]triazol-6-yl]-acetamide and

N-butyl-N-[6-(4-*tert*-butyl-phenyl)-2-methyl-imidazo[2,1-b]thiazol-5-yl]-acetamide.

9. A method for the treatment of pain, comprising administering to a patient in need thereof an effective pain-alleviating amount of a pharmaceutical composition according to Claim 7.

10. A process for the preparation of a bicyclic imidazo-5-yl-amine of Formula Ia,



Ia

the process being three-component reaction and comprising reacting an amidine of Formula II



II

with an aldehyde of Formula III



III

and an isonitrile of Formula IV

R_1- $N^+ \equiv C^-$

IV

in the presence of 20% perchloric acid,

wherein in all formulae,

R^1 denotes $C(CH_3)_3$, $(CH_2)_6CN$, optionally substituted phenyl, C_4-C_8-cycloalkyl, CH_2CH_2R (R = 4-morpholino), 1,1,3,3-tetramethylbutyl or CH_2R^a, wherein R^a represents hydrogen, branched or unbranched C_1-C_8-alkyl, optionally substituted phenyl, CO(OR') (where R' = branched or unbranched C_1-C_8-alkyl), $PO(OR'')_2$ (where R'' = branched or unbranched C_1-C_4-alkyl) or $Si(R^xR^yR^z)$ (where R^x, R^y and R^z in each case independently of one another are branched or unbranched C_1-C_8-alkyl, C_4-C_8-cycloalkyl or phenyl),

R^3 denotes branched or unbranched C_1-C_8-alkyl, C_3-C_8-cycloalkyl, optionally substituted phenyl, optionally substituted 1-naphthyl, 2-naphthyl, quinoline, anthracene, phenanthrene, benzothiophene, benzofurfuryl, optionally substituted pyrrole, 2-pyridyl, 3-pyridyl, 4-pyridyl, optionally substituted furfuryl or optionally substituted thiophene,

X denotes CR^5, N or S,

Y is N, or if X is S, then Y may also be CR^6,

R^4, R^5 and R^6 independently of one another denote hydrogen; branched or unbranched C_1-C_8-alkyl; fluorine; chlorine; bromine; CF_3; CN; NO_2; NHR^f, wherein R^f represents hydrogen, branched or unbranched C_1-C_8-alkyl or optionally substituted phenyl; SR^g, wherein R^g represents hydrogen, branched or unbranched C_1-C_8-alkyl, phenyl, pyridine, benzyl or fluorenyl; OR^h, wherein R^h represents branched or unbranched C_1-C_8-alkyl, optionally substituted phenyl or CO(OR') (R' = branched or unbranched C_1-C_8-alkyl); CO(OR') or $CH_2CO(OR')$, wherein R' in each case has the abovementioned meaning or in the case of the group $CH_2CO(OR')$ also denotes hydrogen, or an optionally substituted phenyl group,

wherein optionally substituted phenyl, optionally substituted 1-naphthyl, optionally substituted pyrrole, optionally substituted furfuryl, optionally substituted thiophene, and optionally substituted alkyl is optionally substituted by one or more substituents selected from the group consisting of a halogen atom, cyano group, nitro group, carboxyl group, hydroxyl group, C_1-C_4 alkylamido group, C_1-C_4 alkylamino group, pyrrolidino group, branched or unbranched C_1-C_6 alkyl group, C_1-C_4 alkyl group substituted with one or more halogen atoms, C_1-C_4 alkoxy group, C_1-C_4 alkoxy group substituted with one or more halogen atoms, and halogen substituted phenoxy group,

excluding compounds wherein R^1 denotes $C(CH_3)_3$, R^3 denotes unsubstituted phenyl, X denotes S, and Y denotes N or CR^6, where R^6 = hydrogen or CH_2-CO_2-ethyl, or wherein R^1 denotes $C(CH_3)_3$, R^3 denotes unsubstituted phenyl, Y denotes NH, and X denotes N or CR^5, where R^5 = CO_2ethyl,

11. A process according to Claim 10, wherein the reaction is carried out in methylene chloride at a temperature of 0°C to 40°C.

12. A process according to Claim 11, wherein the temperature is between 10°C and 20°C.

13. A process according to Claim 11, wherein the compound of Formula II is selected from the group consisting of 3-aminopyrazole, 3-amino-1,2,4-triazole, 2-amino-1,3,4-thiadiazole and 2-aminothiazole.

14. A process for the preparation of a bicyclic imidazo-5-yl-amine of Formula I



I

the process comprising reacting a compound of Formula Ia according to Claim 12 with a compound R^2Hal, wherein Hal represents bromine, iodine or chlorine, or with an optionally substituted isocyanate R^eNCO in the presence of a morpholine resin in methylene chloride for 2 to 24 hours at a temperature between 10°C and 40°C,

wherein optionally substituted isocyanate is optionally substituted by one or more substituents selected from the group consisting of a halogen atom, cyano group, nitro group, carboxyl group, hydroxyl group, C_1-C_4 alkylamido group, C_1-C_4 alkylamino group, pyrrolidino group, branched or unbranched C_1-C_6 alkyl group, C_1-C_4 alkyl group substituted with one or more halogen atoms, C_1-C_4 alkoxy group, C_1-C_4 alkoxy group substituted with one or more halogen atoms, and halogen substituted phenoxy group.

15. The process of Claim 14, wherein after the reaction excess reagents are removed by filtration through a layer of polymer-bonded tris(2-aminoethyl) amine.

16. The process of Claim 14, wherein the compound of Formula Ia is first dissolved in methylene chloride or THF.

17. The process according to Claim 14, wherein R^2Hal is an optionally substituted alkyl chloride, aryl chloride or hydrogen chloride.

18. The process of Claim 14, wherein the morpholine resin is a polystyrene-morpholine resin.